SLSN stock forecast, quote, news & analysis
Solesence Inc is a health-oriented, science-driven company, focused on various skin health, beauty and wellness markets... Show more
Solesence (SLSN) Stock Analysis: Leadership Shifts Amid Downtrend
Key Takeaways
- SLSN shares have declined sharply in recent weeks, hovering near 52-week lows around $1.26 amid low trading volume.
- Director Janet Whitmore made notable insider purchases in December 2025, signaling confidence despite the price weakness.
- Recent SEC filings highlight board changes, including a new director appointment following CEO retirement.
- Q3 2025 earnings showed revenue growth but profitability challenges, contributing to ongoing sentiment caution.
- The company focuses on mineral-based skincare innovations in a competitive beauty sector.
- Investors should monitor upcoming Q4 earnings for strategic updates on operations and growth.
Current Market Snapshot
Solesence Inc. (SLSN) has faced persistent pressure in recent trading sessions, trading near its 52-week low with subdued volume levels. The stock has shed significant ground from earlier highs, reflecting broader challenges in the consumer defensive space. Market cap stands around $89 million, with a trailing P/E ratio exceeding 100, underscoring thin profitability margins. Year-to-date performance remains mixed, but recent weeks have seen accelerated downside amid thin liquidity and limited catalysts. Broader industry headwinds in personal care products have weighed on sentiment, though insider activity offers a counterpoint of optimism.
Recent Developments Driving SLSN Price Action
Solesence Inc. (SLSN), a developer of engineered materials for skincare and advanced applications, has navigated a series of leadership and operational updates in recent months, influencing its stock trajectory. The past 30 days have been marked by minimal fresh catalysts, allowing prior events to dominate price behavior. Notably, director Janet Whitmore executed multiple insider purchases in December 2025, acquiring thousands of shares at prices around $1.73 to $1.92. On December 11, she bought 5,000 shares at $1.89, followed by additional transactions including 1,500 shares on December 30 and 4,787 shares on December 24, totaling over $63,000 in value. These moves, disclosed via Form 4 filings, provided a brief lift but failed to stem the broader downtrend, as shares continued declining from approximately $2.05 in early December to current levels near $1.26—a drop of over 35%.
Earlier in December, on December 1 and 3, the company filed 8-K forms signaling board adjustments, including the appointment of a new director following the CEO's retirement. This came amid ongoing strategic transformation highlighted in Q3 2025 results reported November 11, where revenue reached $14.5 million but EPS fell to -$0.02 from $0.04 year-over-year. Gross margins faced compression, prompting management to emphasize operational efficiencies and product innovation during the earnings call. The post-earnings reaction saw shares plummet 24%, setting the stage for the recent trading range.
Prior to year-end, November developments included the appointment of Yoana Dvorzsak as VP of Innovation and Product Integrity on November 10, aimed at bolstering R&D in mineral-based UV protection and skincare formulations. A settlement with Solarium Brands on November 6 resolved potential disputes, removing overhang but not sparking upside. These events linked to heightened volatility: shares spiked modestly post-insider buys before resuming decline, exacerbated by low volume (averaging under 50,000 shares daily) and absence of analyst coverage. Macro factors, such as softening demand in personal care amid economic uncertainty, amplified the pressure, with SLSN underperforming peers in the consumer defensive sector. Overall, insider confidence contrasts with market skepticism on near-term execution.
2026 Outlook and Key Factors to Monitor
As Solesence advances through 2026, focus will center on executing its strategic pivot toward scalable skincare solutions leveraging proprietary technologies like Active Stress Defense. Revenue growth from engineered nanomaterials and beauty partnerships remains a core driver, building on TTM figures of $62 million, though margin sustainability amid rising costs warrants scrutiny. Leadership stabilization post-CEO transition and new hires in innovation roles could accelerate product launches in mineral sunscreens and daily care, tapping rising consumer demand for clean beauty.
Risks include competitive pressures in the $500 billion global beauty market, supply chain vulnerabilities for raw materials, and debt levels from prior expansions. Regulatory shifts in cosmetic ingredients and FDA oversight of actives represent potential hurdles. Opportunities lie in life sciences diversification, such as medical diagnostics additives, and index inclusion benefits from Russell 2000 membership. Investors should track Q4 2025 earnings, expected in February, for guidance on 2026 revenue targets, cash flow from operations, and progress on cost controls. Broader trends like sustainability preferences and e-commerce growth could bolster positioning if execution aligns.
SLSN in upward trend: price may ascend as a result of having broken its lower Bollinger Band on June 10, 2026
SLSN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 46 cases where SLSN's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for SLSN just turned positive on June 16, 2026. Looking at past instances where SLSN's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .
SLSN moved above its 50-day moving average on June 16, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where SLSN advanced for three days, in of 214 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Momentum Indicator moved below the 0 level on June 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SLSN as a result. In of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SLSN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for SLSN entered a downward trend on June 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. SLSN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.371) is normal, around the industry mean (27.027). P/E Ratio (129.000) is within average values for comparable stocks, (56.263). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.781). SLSN's Dividend Yield (0.000) is considerably lower than the industry average of (0.036). P/S Ratio (1.539) is also within normal values, averaging (2.268).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SLSN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement